cipaglucosidase alfa: clinical use

Prescribing considerations

• Treatment should be supervised by a clinician experienced in Pompe disease or inherited metabolic or neuromuscular disorders.
• Use only with miglustat and assess both components.
• Reassess the overall response and tolerability.
• Home infusion requires medical stability, established infusion tolerance, training and emergency arrangements.
• Record the product name and batch number for traceability.

Contraindications and cautions

• Life-threatening hypersensitivity to cipaglucosidase alfa or an excipient where rechallenge was unsuccessful.
• Any contraindication to miglustat.
• Use particular caution during acute respiratory illness or with compromised cardiac or respiratory function.
• Paediatric safety and efficacy have not been established; experience in older adults and hepatic impairment is limited.

Monitoring

• Observe during and after infusion for anaphylaxis and infusion-associated reactions.
• Ensure cardiorespiratory monitoring and emergency support appropriate to individual risk.
• Monitor for systemic immune-complex reactions, including severe cutaneous or renal features.
• Review mobility, respiratory function, muscle symptoms and overall response.
• Review dizziness, hypotension or somnolence before advising about driving or machinery.

Clinical pharmacology

Cipaglucosidase alfa is recombinant human acid alpha-glucosidase enriched with bis-phosphorylated mannose-6-phosphate glycans. Receptor-mediated uptake delivers it to lysosomes, where active enzyme hydrolyses glycogen. Miglustat reduces loss of enzyme activity in the circulation. Elimination is mainly by hepatic proteolysis.

Formulation and product differences

• Powder for concentrate requiring aseptic reconstitution and dilution before intravenous infusion.
• Each vial is single-use; protect the prepared solution from freezing and shaking.
• Administer with an infusion pump and low-protein-binding inline filter; do not mix with other medicines or share the intravenous line.
• Contains sodium citrate, citric acid, mannitol and polysorbate 80, with a stated sodium content per vial.

Solution for infusion

Route: Intravenous

Strengths: 105 mg